Filtered By:
Specialty: Pharmaceuticals
Education: Learning
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 44 results found since Jan 2013.
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation
IRVINE, CA – May 8, 2020 – Johnson & Johnson Medical Devices Companies* today announced that Biosense Webster, Inc.’s THERMOCOOL SMARTTOUCH® SF Ablation Catheter, evaluated in the PRECEPT study for the treatment of persistent atrial fibrillation (AF), resulted in freedom from any documented, symptomatic atrial arrhythmias at 15 months post-procedure for eight out of ten study participants (80.4 percent).1 Use of the THERMOCOOL SMARTTOUCH SF CATHETER for persistent atrial fibrillation is investigational only. This PRECEPT study data support a Premarket Approval supplement application to the U.S. Food and Drug Adm...
Source: Johnson and Johnson - May 12, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Biosense Webster Launches the OCTARAY ™ Mapping Catheter with TRUEref™ Technology
IRVINE, CA – September 6, 2022 – Biosense Webster, Inc., part of Johnson & Johnson MedTech[†], today announced the release of the OCTARAY™ Mapping Catheter with TRUEref™ Technology powered by the CARTO™ 3 Version 7 System. The OCTARAY™ Mapping Catheter was developed for the mapping of cardiac arrhythmias, including atrial fibrillation (AFib). The catheter has eight splines with improved electrode spacing options to provide shorter and more efficient mapping times than PENTARAYTM NAV ECO Mapping Catheter, which may shorten overall ablation procedure times.[2],[8],[‡] AFib is the most common type of cardi...
Source: Johnson and Johnson - September 6, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen ’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
TITUSVILLE, NJ, November 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first impact summary for its Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now multi-year initiative, designed to create urgency and action around the hidden threat of peripheral artery disease (PAD)-related amputation. In its inaugural year, Save Legs. Change Lives.™ focused on reaching Black Americans, who are up to four times more likely than white Americans to have a PAD-related amputation.1 With this critical initiative, Janssen is focused on helping those at risk of PAD through more th...
Source: Johnson and Johnson - November 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Yaz Settlement News Provided by the Skikos Law Firm, New Claims Still...
Yaz lawsuits continue to result in settlements for victims of blood clots and related injuries such as stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). Readers can learn more at...(PRWeb May 08, 2013)Read the full story at http://www.prweb.com/releases/2013/5/prweb10707101.htm
Source: PRWeb: Medical Pharmaceuticals - May 11, 2013 Category: Pharmaceuticals Source Type: news
If you could propose one idea to help improve health care delivery in the United States, what would it be?
Thumbnail: Tags: conversationsphrma conversationslarry hausnermyrl weinbergchris hansennancy brownContributors: 11621161115911631173Contributions: Read Larry Hausner's bio
Despite the rapid development of innovative technologies in the health care field, we have yet to discover a panacea that will easily transform our health care system into one that provides high-quality and cost-effective care. What we have discovered and come to agree on over the last decade is that our sick care system must be reconfigured to a health care system that emphasizes wellness and prevention. For that reason, I offer ...
Source: PHRMA - June 24, 2013 Category: Pharmaceuticals Authors: rlowe Source Type: news
Yaz Settlements Reach $1.4 Billion Reports the Skikos Law Firm, New...
Women who allegedly suffered blood clot injuries such as stroke, pulmonary embolism (PE), and deep vein thrombosis (DVT) continue to receive Yaz lawsuit settlements in 2013. Readers can learn more at...(PRWeb July 31, 2013)Read the full story at http://www.prweb.com/releases/2013/7/prweb10982921.htm
Source: PRWeb: Medical Pharmaceuticals - July 31, 2013 Category: Pharmaceuticals Source Type: news
NuvaRing Lawsuit and Settlement Update from the Skikos Firm, New...
A growing number of NuvaRing users have filed lawsuits alleging blood clots and related side effects such as stroke, pulmonary embolism, and DVT. Readers can learn more at...(PRWeb January 15, 2014)Read the full story at http://www.prweb.com/releases/2014/01/prweb11482791.htm
Source: PRWeb: Medical Pharmaceuticals - January 15, 2014 Category: Pharmaceuticals Source Type: news
Ornim Medical Announces New Study Results Demonstrating the Value of the CerOx(TM) Cerebral Oxygen Monitor in the Treatment of Patients With Severe Traumatic Brain Injury
Healthcare Professionals Can Learn More About Ornim's Groundbreaking Technology at the International Stroke Conference From February 12-14, 2014, in San Diego
KFAR SABA, ISRAEL--(Healthcare Sales & Marketing Network) - Ornim Medical, Inc., a biomedical ... Devices, Monitoring, NeurosurgeryOrnim Medical, CerOx, cerebral oxygen, traumatic brain injury
Source: HSMN NewsFeed - February 13, 2014 Category: Pharmaceuticals Source Type: news
Amy Comstock Rick - PARKINSONS
By far, the greatest challenge facing the Parkinson’s community today is the lack of disease modifying therapies to slow or stop the progression of the disease.
Parkinson’s disease is one of the most complicated diseases we know of. No two people with Parkinson’s have the same symptoms, and there is no one-size-fits-all approach to treating the disease. People affected are often forced to stop working and manage their disease full time. If Parkinson’s itself isn’t disrupting enough, often the medications used to treat the disease cause a host of side effects that impact the quality of life and sometimes stop bein...
Source: PHRMA - March 27, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news
Centaurs, Not Snake Oil
TheTechtour Healthtech Summit hosted by the International Venture Club in Lausanne is a dating event for European seed, start-up and growth companies looking for investment and for Venture capital and some Pharma/Medtech companies looking to invest. Doug Haggstrom went along to take the pulse of European digital health companies. These companies aren ’t specifically focused on Pharma as partners but it is worth paying attention to how digital health products and services are developing. Pharma developed tools and services will, after all, be compared to these companies in the marketplace and the discipline of proving sta...
Source: EyeForPharma - August 2, 2016 Category: Pharmaceuticals Authors: Tina Boggiano Douglas Haggstrom Source Type: news
The Importance of Talent and Chemistry in New Patient-First Business Models
Forward-thinking life sciences companies are shifting to new patient-centered business models, leaving the traditional volume-first approach behind. This move has tremendous implications, not only for patients but also for the current workforce and future talent: life sciences companies need to design new roles and rethink their talent strategies, including the ways they recruit, train, motivate and retain the best teams.The shift from volume to valueThe historical model in life sciences has been based on selling products, where more was better - more products, more market share and then more profits. Value-based reimburse...
Source: EyeForPharma - August 12, 2016 Category: Pharmaceuticals Authors: Jeff Elton Source Type: news
